[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ChinaNorm\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":256},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,66,88,111,132,156,175,195,216,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100642448","a-study-on-scalp-health-and-integrated-scalp-management-protocols-for-hair-transplant-patients-100642448",false,"NCT07641686","A Study on Scalp Health and Integrated Scalp Management Protocols for Hair Transplant Patients","Inclusion Criteria:\n\n1. Healthy Chinese male subjects aged between 18 and 55 years old;\n2. Diagnosed with androgenetic alopecia, with alopecia grade from Grade II to Grade VI per Hamilton-Norwood classification;\n3. Scheduled to receive hair transplantation; scalp condition is confirmed suitable for trial participation by dermatologist assessment after hair graft surgery;\n4. With or without mild-to-moderate scalp seborrheic dermatitis (SD score ranging from 0 to 9);\n5. No anti-dandruff shampoo used within the latest 14 days prior to enrollment;\n6. No hair dyeing, perming or hair styling cosmetic treatments in the past 30 days;\n7. Able to comply with all scheduled study visits;\n8. Possess normal communication and comprehension capacity;\n9. Agree to regular follow-up visits and complete related questionnaires on time;\n10. Fully understand trial procedures, volunteer to join the study and provide written informed consent.\n\nExclusion Criteria:\n\n1. Suffering from severe scalp seborrheic dermatitis;\n2. Received oral or topical antifungal drugs, glucocorticoids or other therapeutic medicines for seborrheic dermatitis within the preceding 30 days;\n3. Complicated with other scalp diseases (such as psoriasis), or with obvious infection or unhealed wounds on the target treatment area;\n4. Known hypersensitivity to ingredients including selenium disulfide, salicylic acid and related components;\n5. History of autoimmune diseases or severe organic diseases involving heart, brain, lung, liver, kidney and other vital organs;\n6. Past medical history of psychiatric or psychological disorders;\n7. Refuse to sign the written informed consent form;\n8. Currently enrolled in another interventional clinical trial;\n9. Diagnosed with alopecia areata, pseudopelade, cicatricial alopecia or other scalp and hair disorders;\n10. Have taken part in any other clinical trial within the prior 3 months;\n11. Judged as inappropriate for trial participation based on investigator's clinical assessment.",true,"MALE","18 Years","55 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","A total of 120 Chinese male subjects aged 18-50 years who have undergone hair transplantation are planned to be enrolled in this study. Among them, 90 participants with mild-to-moderate scalp seborrheic dermatitis (hereinafter abbreviated as SD) will be stratified and randomly allocated into two groups based on a randomization table with stratification factors including SD severity grading, alopecia classification and age. Subjects in the test product group (hereinafter referred to as the holistic group) will use the test shampoo plus basic shampoo, while those in the basic control group will receive only basic shampoo. The remaining 30 non-SD subjects will constitute the non-SD control group and use basic shampoo alone.\n\n1. Primary Objective To compare pre- and post-treatment changes in clinical, physiological, biological and microecological parameters related to SD manifestations, scalp health and skin barrier repair (including transepidermal water loss, scalp hydration, scalp sebum content, etc.) between the holistic group receiving the investigational shampoo regimen and the basic control group via non-invasive instrumental measurement, clinical assessment, clinical photography and subject self-evaluation. The safety and efficacy of the test product in improving scalp condition and skin barrier function will be evaluated, and its potential underlying mechanisms will be explored.\n2. Secondary Objective To investigate the impacts of the test product versus the control shampoo on hair transplant-associated complications (e.g., folliculitis), wound healing, follicular shedding phase, graft survival rate and hair growth parameters among SD patients.\n3. Exploratory Objective To collect baseline clinical, physiological, biological and scalp microecological data from non-SD recipients after hair transplantation for reference purposes.",[27,28,29],"Hair Transplantation","Seborrheic Dermatitis","Scalp Care","RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-11","ACTUAL",{"date":36,"type":34},"2025-02-21",{"date":38,"type":21},"2027-12-30",{"name":40,"class":41},"ChinaNorm","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":15,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100643765","clinical-study-of-a-facial-cream-for-rosacea-100643765","NCT07637032","Clinical Study of a Facial Cream for Rosacea","Inclusion Criteria:\n\n1. Female Chinese subjects aged 20 to 50 years with Fitzpatrick skin type III-IV;\n2. In good general health, with no chronic diseases or illnesses under treatment;\n3. Assessed by a dermatologist at the baseline visit:\n\n（1）Present with persistent mild erythema on the midface (cheeks, nose, chin and forehead), graded as mild to moderate with a score of 2-3 according to the Clinician's Erythema Assessment (CEA, 0-4 scale) for facial persistent erythema; （2）Graded as mild to moderate with a score of 2-3 based on the papule and pustule assessment scale, inflammatory lesion count and Investigator's Global Assessment (IGA, 0-4 scale); （3）5Have no more than 3 mild inflammatory papules\u002Fpustules on the face; Present with none or only very mild facial telangiectasia; （4）Have not changed daily skin care products in the past three months, and do not use soothing skin care products, medical devices or medical dressings. 4.No additional or replacement skin care products are permitted throughout the study period except the test product.\n\n5.The participants voluntarily join the study, fully understand the trial content and are willing to sign the informed consent form and portrait use authorization.\n\n6.During the entire study period, participants shall comply with the study protocol, use the products provided by the study, and refrain from using other similar products. They are also required to keep study diaries and attend regular follow-up visits as stipulated.\n\nExclusion Criteria:\n\n1. Female participants who are planning to become pregnant, are pregnant or breastfeeding, are within 6 months post-delivery, or refuse to take adequate contraceptive precautions.\n2. Participants currently enrolled in another clinical trial, or who have participated in any other clinical trial within the preceding 3 months.\n3. Participants who have received physical, chemical or cosmetic procedures within 3 months prior to study enrollment.\n4. Participants who have used any medications for rosacea within 4 weeks prior to enrollment, including topical preparations (metronidazole, azelaic acid, erythromycin ointment, etc.), oral agents (minocycline, doxycycline, oral isotretinoin, etc.) or corticosteroids (e.g., hydrocortisone).\n5. Participants with systemic diseases complicated by severe organ damage, cardiovascular diseases, hepatic or renal dysfunction, malignant tumors, poorly controlled chronic diseases, acute infectious diseases, major surgery or trauma, psychiatric disorders; or those requiring topical or systemic medications\u002Ftreatments that may affect atopic dermatitis for other medical conditions.\n6. Participants with other dermatoses (atopic dermatitis, seborrheic dermatitis, eczema, etc.) or evaluative confounding skin conditions (birthmarks, scars, etc.) at the study site.\n7. Participants presenting with symptoms of phymatous rosacea or ocular rosacea at the study site.\n8. Participants with a history of allergic contact dermatitis induced by cleansers or moisturizers.\n9. Participants with a history of allergy to the investigational product or its ingredients, or a history of severe allergic reactions.\n10. Participants who fail to meet compliance requirements, are unable to attend scheduled visits on time, or are unwilling to abide by the study protocol throughout the trial.\n11. Any other conditions that, in the investigator's opinion, make the individual unsuitable for study participation.","FEMALE","20 Years","50 Years",{"count":53,"type":21},76,[24],"This study aimed to evaluate the efficacy, tolerability, and safety of Eucerin Skin Relief Multi-Repair Cream containing the active ingredient SenSiCel™ in improving facial rosacea. A single-center, randomized, negative-controlled clinical intervention design was adopted. A total of 76 Chinese women aged 20-50 years with Fitzpatrick skin types III-IV and mild-to-moderate rosacea (IGA score 2-3, CEA score 2-3, ≤3 inflammatory papules\u002Fpustules) were enrolled. Subjects were randomized in a 1:1 ratio into the test group (using the investigational cream) and the control group (using non-soothing daily facial cream), with an 8-week intervention period and four visits scheduled at baseline, Week 2, Week 4, and Week 8. The primary endpoint was the change from baseline in the Investigator's Global Assessment (IGA) score at Week 8. Secondary endpoints included changes in persistent erythema score, inflammatory lesion count, skin hydration, transepidermal water loss, hemoglobin index, red area proportion, and results of subject self-assessment questionnaires (Likert scale, DLQI). Tolerability and safety were also evaluated via dermatologist assessments and subject feedback. Data were analyzed using descriptive statistics, paired t-test\u002FWilcoxon signed-rank test, and independent t-test\u002FWilcoxon rank-sum test. This study provides clinical evidence for a safe and gentle adjuvant skincare regimen for patients with rosacea and offers a reference for efficacy validation of skincare products containing active ingredients.",[57],"Facial Rosacea","2026-06-04",{"date":60,"type":34},"2026-06-09",{"date":62,"type":34},"2026-04-28",{"date":64,"type":21},"2026-07-31",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":15,"sex":49,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":42},"100636096","clinical-observational-study-on-changes-in-skin-physiological-parameters-following-ablative-and-non-ablative-fractional-laser-treatment-at-different-doses-100636096","NCT07561242","Clinical Observational Study on Changes in Skin Physiological Parameters Following Ablative and Non-Ablative Fractional Laser Treatment at Different Doses","Inclusion Criteria:\n\n* Female Chinese study participants aged 18 to 60 years (inclusive).\n* Fitzpatrick skin phototypes III, IV, or V.\n* Willing to receive non-ablative fractional laser (M22) and ablative fractional laser (CO2) irradiation on the test sites during the study.\n* No primary or secondary lesions (such as scars, ulcers, vesicles, tattoos) on the test sites.\n* Has not participated in any other studies involving the test area (forearms) in the past 2 months.\n* Agrees not to use skin-whitening products on the test area during the study period.\n* In good general health at the time of the study.\n* Volunteers to participate and signs the informed consent form and photo release authorization.\n* Willing to comply with all requirements of the study.\n\nExclusion Criteria:\n\n* Study participants with skin diseases or skin allergies in the test area.\n* Presence of moderate to severe inflammatory skin diseases (e.g., active eczema, acute photosensitive dermatitis, etc.) on the test sites within the past 4 weeks, or those who require treatment with oral or topical corticosteroids or immunosuppressants for skin conditions.\n* On the day of the visit, the investigator judges the presence of significant diffuse erythema, desquamation, or exudation in the test area that may significantly affect skin color measurement.\n* The investigator assesses that the participant is currently suffering from a stable or progressively worsening disease.\n* Participant is planning for pregnancy, is pregnant, or is breastfeeding (applicable to female participants only).\n* Participant with immunodeficiency.\n* Participant has a history of photosensitivity or photoallergy.\n* Participant has a history of skin cancer or malignant melanoma.\n* Presence of significant scars, tattoos, surgical incisions, or pigmented lesions (e.g., prominent birthmarks) in the test area that may affect assessment, and in the investigator's judgment, would impede normal imaging or scoring.\n* Has used high-potency active products containing high concentrations of retinoic acid\u002Fretinol, alpha hydroxy acids, salicylic acid, etc., on the test area frequently (≥3 times per week) for an extended period (≥4 weeks) within the past 3 months, which, in the investigator's judgment, may significantly affect skin texture or barrier status.\n* History of moderate to severe sun exposure (e.g., prolonged outdoor work, travel to seaside\u002Fhigh altitude) within the past 4 weeks, resulting in significant tanning or sunburn in the test area that, in the investigator's judgment, may interfere with study-related readings.\n* Participation in other clinical or consumer testing projects involving the skin condition of the test area within the past 4 weeks.\n* Presence of significant mental or cognitive impairment affecting compliance, and the investigator considers the participant unable to understand the study procedures or complete the tests as required.","60 Years",{"count":74,"type":21},20,"OBSERVATIONAL","This clinical observational study investigates the dose-response relationship between laser energy intensity and skin damage\u002Frepair by applying different parameter sets of fractional ablative (CO2) and non-ablative (M22) lasers to the inner forearms of approximately 20 healthy Chinese female volunteers (aged 18-60, Fitzpatrick skin types III-V) in a single-center, self-controlled design. Each participant receives both laser types on contralateral arms, with four distinct energy\u002Fdensity combinations per laser applied to separate test areas, and the dynamic skin responses are evaluated at baseline, immediately post-treatment, and at 30 minutes, 1, 2, 3, 4 hours, 7 days, and 10 days thereafter through clinical assessments (edema, erythema, etc.), standardized photography, high-frequency ultrasound (Dermascan), and objective instrumental measurements of skin color (Chromameter CM26dG), melanin\u002Fhemoglobin (Mexameter MX18), and barrier function (TEWL via Vapometer). The collected data will be analyzed using descriptive and comparative statistical methods to characterize the acute injury and recovery profiles, aiming to establish a foundational model for future post-procedure cosmetic intervention research.",[78,79],"Skin Barrier Function","Wound Healing","2026-04-24",{"date":82,"type":34},"2026-05-01",{"date":84,"type":34},"2026-03-21",{"date":86,"type":21},"2026-04-30",{"name":40,"class":41},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":15,"sex":49,"minAge":50,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100632058","a-study-on-the-effects-and-mechanisms-of-non-invasive-acupoint-stimulation-in-intervening-in-high-stress-sensitivity-among-young-and-middle-aged-women-with-qi-stagnation-constitution-100632058","NCT07508748","A Study on the Effects and Mechanisms of Non-invasive Acupoint Stimulation in Intervening in High Stress Sensitivity Among Young and Middle-aged Women With Qi Stagnation Constitution","Inclusion Criteria:\n\n* Female, aged 20-40 years.\n* Regular daily routine with relatively fixed wake-up and bedtimes, sufficient sleep (7-9 hours), regular diet, moderate physical activity, and avoidance of shift work.\n* Intact structure of major organ systems, with no active diseases or pathological damage.\n* Regular menstrual cycle (21-35 days) and normal menstrual period (3-7 days).\n* For the experimental group (Qi Yu constitution group):\n\n  * Perceived Stress Scale (PSS-14) score ≥ 43.\n  * Qi Yu Constitution Subscale score ≥ 40.\n  * Diagnosis by a qualified TCM physician according to standard procedures, confirming characteristics of Qi Yu constitution, including (physical symptoms partially required):\n\n    * Body type: Tending to be thin.\n    * Psychological characteristics: Introverted, unstable, sensitive, suspicious, with significant emotional fluctuations.\n    * Somatic symptoms: Fullness or migrating pain in the chest and hypochondrium, frequent sighing; sensation of a foreign body in the throat (globus hystericus); sleep disturbances (difficulty falling asleep, early awakening). Poor appetite, frequent belching.\n    * Tongue and pulse: Pale red tongue with thin white coating, wiry and thin pulse.\n* For the control group (non-Qi Yu constitution group):\n\n  * Perceived Stress Scale (PSS-14) score ≤ 42.\n  * Qi Yu Constitution Subscale score \\\u003C 30.\n  * No relevant clinical manifestations upon TCM examination.\n* Signed informed consent form, voluntarily participating in the trial.\n* Willing to comply with all testing requirements.\n* No infection or bleeding tendency on the skin of the five acupoint areas (GV20\u002FBaihui, LI4\u002FHegu, LR3\u002FTaichong, PC6\u002FNeiguan, SP6\u002FSanyinjiao), not affecting the use of the study products.\n\nExclusion Criteria:\n\n* Participation in any other clinical trial evaluation within the past 1 month.\n* Presence of organic diseases, such as various malignant tumors, certain chronic diseases (heart disease, diabetes, anemia, etc.), certain gynecological diseases (uterine fibroids, endometriosis, severe mammary hyperplasia, etc.), or certain endocrine diseases (hyperthyroidism or hypothyroidism, etc.).\n* Individuals with hypothalamic-pituitary-adrenal (HPA) axis dysfunction, such as those with endocrine diseases (e.g., hyper\u002Fhypothyroidism, Cushing's syndrome, congenital adrenal hyperplasia, primary chronic adrenocortical insufficiency).\n* Individuals diagnosed with major depressive disorder or anxiety disorder, bipolar disorder, schizophrenia, etc.\n* Use of antidepressants, anti-anxiety medications, glucocorticoids, or immunosuppressants within the past 4 weeks.\n* Recent (within the past 3 months) suicidal ideation or self-harm behavior.\n* Receipt of acupuncture, massage, or other TCM treatments or psychological interventions (e.g., cognitive behavioral therapy) within the past 4 weeks.\n* Suffering from autoimmune diseases requiring long-term use of hormones.\n* Alcohol or drug dependence.\n* Experienced major stressful life events (e.g., bereavement of a close relative suffering a major psychological blow) in the past year.\n* Physically weak or unable to tolerate the arithmetic stress in the MIST task.\n* Conditions such as epilepsy, hypertension, or heart disease that are unsuitable for undergoing induced psychological stress.\n* Inability to cooperate in completing the MIST task (e.g., due to visual\u002Fauditory impairment, cognitive dysfunction).\n* Inability or unwillingness to attend all study visits and comply with the treatment regimen.","40 Years",{"count":96,"type":21},90,[24],"This is a randomized, placebo-controlled trial with a cross-over component. It investigates the effect of non-invasive acupoint stimulation on stress in young and middle-aged women. A total of 90 participants will be enrolled: 60 with a Liver-Qi Stagnation constitution and high perceived stress, and 30 without this constitution as a non-intervention baseline control. The 60 participants with the target constitution will be randomized into two groups. One group (n=30) will undergo a cross-over intervention, sequentially receiving steam-warm acupressure and simple acupressure (at five acupoints) in a randomized order, separated by a washout period. The other group (n=30) will receive placebo stimulation. The primary outcome is the change in the Perceived Stress Scale (PSS-14) score. Secondary outcomes include physiological stress responses.",[100,101],"Qi Stagnation Constitution","Acupoints","NOT_YET_RECRUITING","2026-03-27",{"date":105,"type":34},"2026-04-02",{"date":107,"type":21},"2026-04-07",{"date":109,"type":21},"2026-07-30",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":15,"sex":49,"minAge":50,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":42},"100624912","a-quantitative-cross-sectional-and-observational-study-to-characterize-age-related-structural-changes-in-facial-skin-of-chinese-women-using-line-field-confocal-optical-coherence-tomography-lc-oct-100624912","NCT07415798","A Quantitative, Cross-Sectional and Observational Study to Characterize Age-Related Structural Changes in Facial Skin of Chinese Women Using Line-Field Confocal Optical Coherence Tomography (LC-OCT)","Inclusion Criteria:\n\n1. Chinese female, aged between 20 and 70 years (inclusive) at the time of signing consent.\n2. Willing and able to provide written informed consent.\n3. Fitzpatrick Skin Phototype II or III.\n4. Willing to comply with all study procedures, including removal of facial makeup and avoidance of intensive skincare (e.g., retinoids, strong acids) on the test areas for 3 days prior to the visit as per instructions.\n\nExclusion Criteria:\n\n1. Pregnant, planning pregnancy, or breastfeeding (as hormonal changes significantly affect skin properties).\n2. Presence of temporary tanning, sunburn, or significant erythema on the face or measurement areas.\n3. Presence of facial piercings, tattoos, too much fluff or significant scarring that would interfere with imaging or measurements in the areas of interest.\n4. History of any aesthetic or surgical procedure on the face (e.g., laser therapy, chemical peels, injectable fillers, botulinum toxin, plastic surgery) within the past 12 months.\n5. Current diagnosis or visible signs of a skin disease (e.g., psoriasis, eczema, active acne, rosacea) or a systemic disease known to affect the skin (e.g., diabetes, lupus) on the face or measurement areas.\n6. Use of systemic medications known to affect skin physiology (e.g., oral retinoids, immunosuppressants, long-term corticosteroids) within the past 3 months, or for a cumulative duration of ≥6 months within the past 2 years.\n7. Participation in another clinical study on the face or arms within the past 1 month.","70 Years",{"count":119,"type":21},100,"This is a single-center, non-interventional, observational, cross-sectional clinical study designed to quantitatively and qualitatively characterize skin properties in a cohort of 100 Chinese female Subjects aged 20 to 70 years. The study involves no product application and poses minimal risk to participants. The primary objectives are to establish a comprehensive skin aging profile database, characterize skin color, aging signs, and biomechanical properties, and create a histomorphometric database for the development and validation of ordinal photographic scales for aging research. Data will be collected through questionnaires, clinical assessments (including LC-OCT imaging), standardized photography, and non-invasive biophysical measurements. All procedures will be conducted in accordance with the ethical principles originating from the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, and the relevant laws and regulations of China (including the \\*Measures for the Ethical Review of Biomedical Research Involving Human Subjects\\*). All data will be anonymized and stored securely.",[122,123],"Female","Facial Skin","2026-02-10",{"date":126,"type":34},"2026-02-17",{"date":128,"type":34},"2026-01-15",{"date":130,"type":21},"2027-01-15",{"name":40,"class":41},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":15,"sex":138,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100622465","the-impact-of-12-week-retention-of-nutrients-on-skin-and-the-perception-of-physical-health-status-100622465","NCT07383974","The Impact of 12 Week Retention of Nutrients on Skin and the Perception of Physical Health Status","Inclusion Criteria:\n\n1. Chinese adults of Asian descent aged 18 and above;\n2. Daily fruit and vegetable intake \\\u003C 240g (calculated based on the fruit and vegetable section of the food frequency questionnaire);\n3. S3 measurement index \\\u003C 30000;\n4. Participants must possess basic Chinese reading comprehension and expression skills, and be able to independently complete questionnaire surveys;\n5. Voluntary participation in the test and signing of the informed consent form;\n6. Willingness to comply with all evaluation requirements.\n\nExclusion Criteria:\n\n1. Presence of open facial skin lesions, clearly visible scars, acne marks, etc.;\n2. Skin lesions, scars, or significant pigmentation on the hand measurement area;\n3. Symptoms of skin disease on the face or hand measurement areas;\n4. Having undergone medical aesthetic procedures within the last 6 months;\n5. Participation in other clinical trials involving product use within the last 3 months;\n6. Use of health supplements or nutritional supplements (e.g., vitamins, minerals) within the last 1 month;\n7. Currently planning for pregnancy, pregnant, or lactating;\n8. Presence of any disease under current treatment;\n9. Any other health issues or chronic diseases that affect behavioral or cognitive abilities;\n10. Other iatrogenic reasons identified by experts or professionals that may affect the evaluation results.\n\nThe S3 instrument refers to a Raman spectroscopy-based biophotonic scanner. The threshold for the S3 screening value is based on previously published literature, which indicated that participants with a daily fruit and vegetable intake of less than 240g had an average Raman spectroscopy biophotonic scanner score below 25,000. However, considering practical recruitment challenges, the inclusion criterion was set at \\\u003C 30,000. The S3 device measures the Skin Carotenoid Index, a non-invasive biomarker reflecting skin carotenoid levels.","ALL",{"count":20,"type":21},[24],"This is a randomized, double-blind, placebo-controlled clinical trial exploring the effects of a 12-week dietary supplement regimen on skin condition and perceived overall health status.\n\nThe study will involve 120 healthy Chinese adults aged 18 and above with low daily fruit and vegetable intake. Participants will be randomly assigned to one of two groups: one group will take a combination of Nu Skin's Vitamin C \\& Green Tea Capsules and Multivitamin \\& Mineral Capsules, while the other group will take a matching placebo.\n\nThe primary goal is to assess if the supplement combination improves skin health after 12 weeks, measured through specialized facial imaging (assessing spots, redness, evenness) and probe measurements (assessing elasticity, moisture, gloss). Secondary goals include evaluating changes in participants' self-perceived health status (via quality of life, fatigue, and digestive health questionnaires), psychological resilience, memory, and exploring a new method for measuring skin carotenoid levels.\n\nThis study is not intended to verify the approved health functions of the products but to explore the potential combined effects of antioxidant and nutritional supplementation on skin and general well-being.",[143,144,145,146,147],"Healthy Volunteers","Dietary Supplementation","Skin Health","Health Status","Antioxidants","2026-01-26",{"date":150,"type":34},"2026-02-03",{"date":152,"type":34},"2025-11-03",{"date":154,"type":21},"2026-02-02",{"name":40,"class":41},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":15,"sex":138,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100608203","study-on-carotenoid-based-instrumental-index-100608203","NCT07198503","Study on Carotenoid-Based Instrumental Index","Inclusion Criteria:\n\n1. Chinese individuals of Asian ethnicity aged 18 years or older.\n2. Basic proficiency in reading and writing Chinese, sufficient to independently complete questionnaires.\n3. Voluntary participation with signed informed consent.\n4. Willingness to comply with all assessment requirements.\n\nExclusion Criteria:\n\n1. Presence of open facial lesions, prominent scars, or visible acne marks.\n2. Currently planning pregnancy, pregnant, or breastfeeding.\n3. Ongoing treatment for acute or severe medical conditions.\n4. Significant impairments affecting cognitive or behavioral abilities.\n5. Other medical reasons identified by experts or professionals that may interfere with the assessment results.",{"count":163,"type":21},600,"Nu Skin (China) Daily-Use\\&Health Products Co.,Ltd. has developed biophotonic scanners based on Raman spectroscopy, which measures skin carotenoid levels through hand skin scanning. In this study, the new Prysm device, which adopts new technology in a lower cost and more portable form, was used to measure skin carotenoid levels in a population, and the relationships between these levels and dietary habits and lifestyle factors were analyzed. The collected data included basic demographic information such as age, gender, smoking status, use of health products or nutritional supplements, and exercise habits, as well as physiological indicators such as BMI and body fat percentage. Subjective assessments were also obtained, including questionnaires on diet, skin condition, physical health, lifestyle, psychological status, and memory performance, alongside skin image analyses capturing parameters such as ITA°, L\\*, a\\*, b\\*, glossiness, erythema, and pigmentation.",[166],"Skin Carotenoid Status","2025-09-29",{"date":169,"type":34},"2025-09-30",{"date":171,"type":34},"2025-09-06",{"date":173,"type":21},"2025-10-16",{"name":40,"class":41},{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":138,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":4},"100603242","a-clinical-observational-study-evaluating-the-efficacy-of-cerave-neuroceramide-intensive-repair-body-lotion--100603242","NCT07133971","A Clinical Observational Study Evaluating the Efficacy of Cerave Neuroceramide Intensive Repair Body Lotion .","A Clinical Observational Study Evaluating the Efficacy of Cerave Neuroceramide Intensive Repair Body Lotion in Improving Dry Skin in the Elderly","Inclusion Criteria:\n\n* Individuals with moderate to severe skin dryness as assessed by a clinician (ODS score of 2 or 3)\n* Individuals with moderate to severe self-reported skin itching as assessed by a clinician (NRS ≥ 1)\n* Individuals aged 55 years and older\n* Open to patients with one or more of the following conditions:\n\n  1. History of atopic dermatitis;\n  2. Currently using a stable medication regimen prescribed and monitored by a physician (ongoing use), where the medication has side effects causing skin dryness (e.g., statins, calcium channel blockers, diuretics, antiplatelet agents, ACE inhibitors, beta-blockers, adrenergic receptor agonists, immunosuppressants, etc.);\n  3. Patients with systemic diseases associated with dryness (diagnosed and managed by a physician), such as diabetes, hyperthyroidism, hypothyroidism, or hemodialysis.\n* Voluntarily participate in the trial, understand and agree to sign the informed consent form, and agree to follow the study protocol throughout the study period, including using the study-provided products, not using other similar products, completing a diary, and attending regular follow-up visits as required by the trial.\n\nExclusion Criteria:\n\n* Individuals with a history of allergy, allergic reaction, or hypersensitivity to any component of the study product (Cerave Neuroceramide Moisturizing Repair Body Lotion);\n* Individuals with a history of allergic contact dermatitis secondary to the use of moisturizing products;\n* Individuals with any clinical manifestations or other conditions at the treatment site that the physician deems may affect the evaluation or results of the study product;\n* Individuals who are unable or unwilling to attend all study visits and adhere to the treatment regimen;\n* Individuals who have participated in any other drug clinical studies within the past 3 months prior to the start of the trial.",{"count":183,"type":21},210,"This study is a single-center observational clinical study aimed at evaluating the impact of Cerave Neuroceramide Moisturizing Repair Body Lotion on the quality of life, improvement in skin condition, and satisfaction with the product experience among individuals with moderate to severe dry skin associated with aging. The study plans to recruit approximately 210 male or female participants aged 55 years or older with moderate to severe skin dryness in the affected areas (accounting for a dropout rate and protocol violation rate of no more than 5%), and will screen participants based on inclusion and exclusion criteria to ensure that at least 200 participants complete the study. Participants entering this study will be categorized based on ODS and NRS scores into: moderate or severe skin dryness (moderate-grade 2, severe-grade 3), with the sample size ratio between moderate and severe groups maintained at 1:1. This study will last for 4 weeks and include 2 visits. Visits will be conducted at baseline (T0) and week 4 (T4w). The window period for the week 4 (T4w) visit is ±2 days. This study does not involve randomization. All study participants will use Cerave Neuroceramide Moisturizing Repair Body Lotion on areas of skin dryness.",[186],"Dry Skin in the Elderly","2025-08-20",{"date":189,"type":34},"2025-08-21",{"date":191,"type":21},"2025-08-22",{"date":193,"type":21},"2026-01",{"name":40,"class":41},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":15,"sex":49,"minAge":50,"maxAge":94,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":42},"100598129","instant-flush-redness-clinical-efficacy-study-100598129","NCT07067476","Instant Flush Redness Clinical Efficacy Study","A Randomized, Double-Blind, Split-Face Clinical Study to Evaluate the Redness Relief Efficacy of Instant Flush Products in Subjects With Sensitive Skin","Inclusion Criteria:\n\n1. Chinese women aged from 20-40 years old.\n2. Self-declared mild sensitive skin.\n3. Self-declare with skin concerns of redness and easy to flush.\n4. Willing to be exposed to infrared light on the facial skin to induce facial redness(can tolerate heat sensation on the face).\n5. Clinical grading of skin redness (visual) ≥ 4 after infrared light induction (7-8 mins) by dermatologist.\n6. No disagreement of dermatologist because of other reasons that exclude the parficipation of the subject.\n7. In general good health at the time of the study.\n8. Willing and able to participate as evidenced by signing of informed consent and photo release\n\nExclusion Criteria:\n\n1. Allergic to infrared light\n2. Pregnant or breast-feeding woman or woman planning pregnancy during the study.\n3. Subject deprived of rights by a court or administrative order.\n4. Major subject to a guardianship order.\n5. Subject residing in a health or social care establishment.\n6. Patient in an emergency setting\n7. Subject with a skin disease in the test areas (particularly e.g, acne, rosacea, eczema).\n8. Subjects with history, of atopy, allergic reactions, irritation or intense discomfort feelings to topical-use products, medication, cosmetic: or personal care products or ingredients.\n9. Subject presenting a stable or progressive serious disease (per investigator's assessment).\n10. Immuno-compromised subject.\n11. Subject presenting excessive exposure to sunlight or UV radiation (investigator's assessment).\n12. Subjects regularly practicing aquatic or nautical sports.\n13. Subjects regularly attending a sauna.\n14. Subject with cardiovascular or circulatory history.\n15. Subject with a history of skin cancer or malignant melanoma.\n16. Intake of antihistamines, antibiotics, corticosteroids, non-steroidal anti-inflammatories or immune-suppressants in the last 6 months before study.",{"count":203,"type":21},60,[24],"The goal of this clinical trial is to learn if an anti-redness emulsion can help lower facial redness caused by heat in healthy adult women. The main questions it aims to answer are:\n\n* Does the anti-redness emulsion lower facial redness better than purified water?\n* Is the product safe and comfortable to use?\n\nResearchers will compare the anti-redness emulsion to purified water using a split-face method.\n\nParticipants will:\n\n* Receive infrared light on their face to trigger redness\n* Apply the anti-redness emulsion to one side of their face and purified water to the other side\n* Have their facial redness measured at different time points using photography, imaging devices, and skin redness tests\n* Answer questions about their experience with the products",[207],"Sensitive Skin","2025-07-14",{"date":210,"type":34},"2025-07-16",{"date":212,"type":21},"2025-07-15",{"date":214,"type":21},"2025-10-31",{"name":40,"class":41},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":138,"minAge":223,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":4},"100596328","an-observational-clinical-study-to-evaluate-the-efficacy-of-the-cerave-skin-care-line-100596328","NCT07044024","An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line","An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line in Improving Mild to Severe Acne on the Face","Inclusion Criteria:\n\n* Chinese males and females, age eligible greater than or equal to 13 years old;\n* Be in good health and free from any other chronic disease or disease under treatment;\n* Be judged by a dermatologist at the Baseline visit:\n\nMild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA)11,12 (Mild - Grade 1 or Grade 2) Acne Grading Scale (GEA) - Scale 1 or 2, Moderate - Scale 3, Severe - Scale 4 or above);\n\n* Initiation of acne treatment within the last 3 months with medications that include, but are not limited to, the following\n\n  1. Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, 0.1% adapalene\u002FBPO. b) Topical medications: benzoyl peroxide (BPO), retinoic acid, adapalene, isotretinoin, azelaic acid, adapalene 0.3% adapalene\u002FBPO, retinoic acid\u002Fclindamycin, BPO\u002Fclindamycin;\n  2. Oral medications: antibiotics, spironolactone, isotretinoin, etc; If Global Evaluation Acne Grading Scale (GEA) classification is ≥2, continuous use of the above medications for at least 2 weeks prior to the baseline visit is required.\n\n     If the Global Evaluation Acne Grading Scale (GEA) is ≥2, acne treatment with the above medications should be continued for at least 2 weeks before the baseline visit; If oral medication is used, acne treatment should be continued for at least 4 weeks prior to the baseline visit.\n\n     Exclusion Criteria:\n* Adult female study participants who intend to plan a pregnancy, or who are pregnant, breastfeeding, within 6 months of delivery, or who are unwilling to take the necessary precautions to avoid pregnancy;\n* Study participants who are currently enrolled in another clinical study or have been enrolled in another clinical study within 3 months;\n* Study participants who have undergone physical, chemical, or cosmetic surgery within 3 months prior to enrollment;\n* Systemic diseases with severe organ damage, cardiovascular diseases, liver or kidney dysfunction, malignant tumors, chronic diseases with unstable control, acute infectious diseases, major surgeries or traumas, psychological and psychiatric disorders, or other diseases that require topical or systemic use of medications or treatments that have an effect on acne;\n* The study site is associated with other skin disorders (atopic dermatitis, rosacea, rosacea, eczema, etc.) or the presence of other skin conditions that interfere with evaluation (birthmarks, scarring, etc.);\n* Participants in the study have a history of allergic contact dermatitis caused by cleansers (facial cleansers)\u002Fmoisturizers;\n* History of allergy or severe allergy to the products (Sensitive Skin products) and related ingredients provided in the study;\n* Study participants who are unable to follow compliance requirements, or who are known to be unable to attend visits on time, or who are unwilling to comply with the study protocol arrangements for the duration of the study;\n* Any clinical presentation or other illness in the required observation area that, in the opinion of the investigator, may affect the study product assessment or results.\n* Study participants had received medical aesthetic treatments (including but not limited to photofacial type treatments, fruit acid resurfacing, etc.) within 3 months prior to enrollment.","13 Years",{"count":225,"type":21},240,"This is an observational clinical study to evaluate the efficacy of the CeraVe Skin Care product line in improving mild to severe facial acne. Primary Objective: To evaluate the efficacy of CeraVe Skincare products in improving mild to severe facial acne through clinical observation by dermatologists of skin conditions before and after the use of the test product kit during the course of acne medication, as well as to collect concurrent feedback on the quality of life of this population and their experience with and satisfaction with the test product. Secondary objectives: 1. To collect feedback on the experience, satisfaction and quality of life improvement of CeraVe products through subjective evaluation of the subjects after using the products, in order to gain a deeper understanding of the comprehensive performance of the products in actual application; 2. To verify the tolerance of CeraVe products through clinical evaluation of the facial skin condition before and after the use of the products by dermatologists; 3. To evaluate the effectiveness of CeraVe products in improving acne. CeraVe is a dermatologist's clinical assessment of facial skin conditions before and after use to verify the tolerability and safety of CeraVe's skin care products. The study is designed to enroll approximately 240 male and female study participants aged 13 years or older with mild to severe facial acne, with a minimum sample size of 200 subjects based on a 15% dropout rate during the trial period and a protocol violation rate of no more than 5%. Participants entering the study will be classified as having mild, moderate, or severe acne according to the Global Evaluation Acne Grading Scale (GEA) (mild-grade 1 or grade 2, moderate-grade 3, severe-grade 4 or higher), with a sample size of mild acne:moderate acne:severe acne of approximately 1:1:1. The study was conducted over an 8-week period with 3 visits. They were conducted at the baseline visit (T0), week 4 follow-up (T4w) and week 8 follow-up (T8w). The window period was ±1 day for the week 4 (T4w) visit and ±2 days for the week 8 (T8w) visit. The primary evaluation parameters included: clinical assessment and product tolerance assessment by the dermatologist, patient self-assessment and questionnaires.",[228],"Acne","2025-06-23",{"date":231,"type":34},"2025-06-29",{"date":233,"type":21},"2025-06-27",{"date":214,"type":21},{"name":40,"class":41},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":138,"minAge":17,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":255,"locationsCount":42},"100594656","a-clinical-study-evaluating-the-application-of-la-roche-posays-new-b5-multi-effect-soothing-and-repairing-cream-on-individuals-with-facial-atopic-dermatitis-100594656","NCT07022288","A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis","A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis.","Inclusion Criteria:\n\n* 1\\) Chinese males and females aged 18 to 65 years old (including 18 and 65 years old); 2) In good health, without any other chronic diseases or diseases under treatment; 3) Have received atopic dermatitis drug treatments, including but not limited to:\n\n  1. Topical glucocorticoids (TSC), such as 0.05% fluticasone propionate cream, 0.1% mometasone furoate cream, 0.1% hydrocortisone butyrate cream, 0.1% triamcinolone acetonide cream, 0.25% hydrocortisone cream, 0.05% desonide cream\u002Fointment, etc.;\n  2. Topical calcineurin inhibitors (TCI), such as 1% pimecrolimus cream, 0.03%\u002F0.1% tacrolimus ointment, etc.;\n  3. Oral antihistamines, such as cetirizine hydrochloride tablets, loratadine tablets, ebastine tablets, azelastine hydrochloride tablets, etc.;\n  4. Other topical medications, such as zinc oxide oil (paste), black bean distillate oil ointment, topical phosphodiesterase 4 (PDE-4) inhibitor ointment, physiological sodium chloride solution, and other wet dressing medications, etc.; 4) At the baseline visit (Baseline), as determined by a dermatologist:\n\n     * Meeting Yao's diagnostic criteria,\n     * Atopic dermatitis severity is mild (Investigator Global Assessment, IGA ≤ 2 points);\n     * The condition is in a stable phase and no longer requires topical drug treatment 5) At the baseline visit (Baseline), trans-epidermal water loss (TEWL) measurement value \\> 15g\u002Fm²\u002Fh 6) Voluntarily participate in the trial, understand and be willing to sign the informed consent form; 7) Willing to follow the study protocol to use the products provided by the study throughout the study period, not use other similar products, keep diaries, and attend regular follow-ups and other trial requirements.\n\nExclusion Criteria:\n\n* 1\\) Study participants who plan to become pregnant, are pregnant, are breastfeeding, are within 6 months after childbirth, or are unwilling to take necessary precautions to avoid pregnancy; 2) Study participants with atopic dermatitis in an acute exacerbation phase; 3) Study participants currently participating in other clinical trials or who have participated in other clinical trials within the past 3 months; 4) Study participants who used functional moisturizers containing skin microecology-regulating ingredients within 1 week before enrollment; 5) Study participants who received physical, chemical, or cosmetic surgical treatments within 3 months before enrollment; 6) Study participants with systemic diseases (severe organ damage), malignant tumors, poorly controlled chronic diseases, acute infectious diseases, major surgeries or trauma, psychological or mental disorders, or who require local or systemic use of drugs\u002Ftreatments affecting atopic dermatitis due to other diseases; 7) Study participants who experience explosive exacerbation of atopic dermatitis lesions after using the treatment regimen; 8) Study participants with other skin diseases (acne, rosacea, eczema, infections, tumors, etc.) at the study site or other skin conditions interfering with evaluation (birthmarks, scars, etc.); 9) Study participants with a habit of scratching or squeezing atopic dermatitis lesions; 10) Study participants with a history of allergy to the products and related ingredients provided in the study; 11) Study participants with poor compliance, known inability to attend visits on time, or unwillingness to follow the study protocol during the study period; 12) Other circumstances where the investigator deems it inappropriate for the participant to join the study.","65 Years",{"count":53,"type":21},[24],"This study plans to recruit 76 subjects in accordance with the above inclusion and exclusion criteria, with at least 60 subjects completing the study. The study period is 8 weeks, and the subjects need to visit the research center 4 times. After the subjects are enrolled, they will be randomly divided into two groups, including the experimental product group and the control product group.\n\nThe physiological indicators of the skin were measured by objective instruments and compared with those of ordinary moisturizers without skin microecological regulation components to evaluate the repair promotion effect and improvement of La Roche-Posay's new B5 Multi-Effect Soothing and Repairing Cream on the affected areas of patients with mild atopic dermatitis on the",[248],"Atopic Dermatitis of Face","2025-06-12",{"date":251,"type":34},"2025-06-15",{"date":253,"type":34},"2025-04-20",{"date":214,"type":21},{"name":40,"class":41},""]